Our anti-CD122 antagonist antibody, known as ANB033, targets the common beta subunit shared by the IL-15 and IL-2 receptors.

IL-15 signaling mediates the survival and maintenance of tissue resident memory T cells (TRM) 

The presence of long-lived and persistent TRM have been shown to drive tissue-specific immune-mediated inflammation 

We anticipate submitting an IND for a Phase 1 clinical trial with ANB033 during the first half of 2024.